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Abstract
Background: Severe burns of hands and arms are complex and challenging injuries. The Standard of care
(SOC) – necrosectomy with skin grafting – is often associated with poor functional or aesthetic outcome. Enzymatic
debridement (ED) is considered one promising alternative but, until recently, results proved to be highly variable.
Methods: Between 04/2014 and 04/2015, 16 patients with deep partial- to full-thickness burns of the upper extremities
underwent enzymatic debridement (ED) in our Burn Center and were evaluated for extent of additional surgery,
wound healing, pain management and functional parameters.
Results: Following ED, no further surgical intervention was required in 53.8 % of the study population. In patients who
required surgical treatment, the the skin-grafted area could be reduced by 37.0 % when compared to initial
assessment. Time from injury to ED was 24.4 h and patients were able to start physical therapy after 2.0 days
but suffered from prolonged wound closure (28.0 days). Regionally administered anesthesia proved to be
superior to pain medication alone as pain levels and consumed morphine-equivalent were lower. Post-demission
follow-up showed good functional results and pain levels with low scores in two self-report questionnaires (DASH,
PRWE-G) but 3 patients reported increased susceptibility to shear stress. Based on these early experiences, we
developed a 3-step algorithm for consecutive patients allowing appropriate and individualized treatment selection.
Conclusions: We see a potential benefit for ED in the treatment of severely burned hands and forearms but further
investigations and proper prospective, randomized controlled trials are needed to statistically support any outlined
assumptions.
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Background
Burns are common injuries associated with substantial
morbidity and mortality. Over 2000 cases have been
treated in German Burn Centers in 2013 [1]. Estimates for
the frequency of hand involvement vary between 30–60
and 80 % of newly admitted patients [2, 3]. Standard of
care (SOC) for deep partial- and full-thickness burns is
necrosectomy and skin grafting but, especially when
conducted on hands and forearms, often associated with
poor aesthetic and functional outcome [4].
Initial assessment of both burn extent and depth can
prove to be difficult and inadequate. Additionally, burn
wounds can progress and change over time, leading to
an unanticipated need for surgery [5]. In combined
partial- and full-thickness wounds, conventional surgical
intervention may cause unnecessary tissue loss, since
vital tissue might be unnecessarily removed. This can be
detrimental for functional outcomes, especially when
distal extremities with a thin soft tissue envelope are
treated. Fingers and hands have a complex anatomy,
sparse tissue coverage and present vessels, nerves and
tendons confined on a very small space [4]. Since SOC
might lead to unsatisfying outcomes in some patients,
new therapeutic options are still required. Enzymatic
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debridement (ED) is considered one promising alterna-
tive and has therefore been extensively studied since the
Second World War. But, until recently, results proved to
be highly variable [6].
NexoBrid® (NXB) is an enzymatic debriding agent that
was EMEA-approved in late 2012. Its active ingredient
constitutes of a concentrate of proteolytic enzymes
enriched in bromelain derived from the stem of the
pineapple plant. It is indicated for enzymatic debridement
in adults with deep partial- and full-thickness thermal
burns [7]. Application is possible outside the operation
theatre as long as sufficient analgesia is ensured during
this otherwise painful debridement procedure.
Previous studies reported promising results. A large
multi-center, randomized controlled clinical trial con-
ducted on 182 patients between 2006 and 2009 postu-
lated significant reductions in time from injury to
complete debridement, need for surgery, autografting
and area of burns excised when compared to SOC. In a
subgroup of hand burns, additional benefit was seen as
these patients exhibited earlier time to wound closure
and better long-term results [8]. Similar findings had
previously been reported in a retrospective data analysis
of 69 hand burns [2]. Furthermore, the number of
escharotomies could be reduced, since initial ED suffi-
ciently decreased compartment or interstitial pressures.
In both studies, no ED treated hand required escharot-
omy compared to about 10 % in SOC [2, 8]. However,
although these results suggest a benefit of ED especially
in hand burns, no prospective correlative studies have
yet been conducted.
In April 2014, we started using NXB on qualifying
burns of the upper extremities as a possible alternative
to surgical necrosectomy and skin grafting. We hypothe-
sized, that these patients would benefit from reduced
need for surgery and absent morbidity often associated
with SOC, e.g. functionally impairing tissue loss and
subcutaneous tissue damage. We also evaluated the time
to onset of physical therapy (PT), wound closure and
early functional outcome. Additional emphasize was put
on pain management accompanying ED when compar-
ing local to regionally administered anesthetic measures.
With this article, we want to provide an overview of
the problems, experiences and results gathered when
using ED for deep burns of the hands and forearms.
Methods
Between 04/2014 and 04/2015, all patients admitted to
our Burn Intensive Care Unit (BICU) showing deep
partial- to full-thickness upper extremity burns were
treated by ED on not more than 15 % TBSA within the
first 48 h after admission. Fingers and hands were priori-
tized even when injuries were exceeding proximally or
included additional body regions.
Upon arrival in the Burn Trauma Bay (BTB), standard
admission protocol was performed which included
complete undressing of the patient and initial debride-
ment with opening of present blisters under antiseptic
conditions. Standardized escharotomy by monopolar
cautery was performed if injuries included circumferen-
tial burns. This was not regarded as exclusion criterion
and ED was not performed as a replacement for surgical
escharotomy. When wound bed was cleaned, a polihexa-
nide gel was applied and sterile wound dressings were
completed by multilayered greased gauzes, cotton and
elastic bandages before admission to BICU. If burn
depth on the upper extremities was categorized as po-
tential deep partial- to full-thickness by the attending
physician, dressings were opened and reassessed within
48 h (Fig. 1). If the patient qualified for ED, sufficient an-
algesia was ensured by either timely administration of
p.o./i.v. pain medication or ultrasound-guided placement
of brachial plexus nerve block by an anesthesiologist [9].
Additional pain medication was given if needed. Some
patients received the application under anesthesia since
severity of their total burn injuries had required intub-
ation and ongoing sedation.
Wounds were covered in bandages rinsed in a 0.04 %
polihexanide solution (Serasept™ 2, Serag-Wiessner, Naila,
Germany) and soaked for 2 h before and after application
of the actual debriding agent (Fig. 2). Preparation also in-
cluded separation of the wound bed from intact skin by
vaseline. Enzymatic reaction was then started by mixing
the powder ingredient into the carrier gel, creating a
golden viscous mass (Fig. 3) that was applied to the wound
bed under sterile conditions (approx. 2 g/% TBSA). We
then formed an occlusive dressing with two large plastic
self-adhesing sheets (Fig. 4). Enzymatic debridement time
was at least 4 h before dressings were opened and detritus
was removed by sterile spatulas and rinsing in saline
solution. The final step consisted of another 2 h soaking
period before standardized greased gauze dressings
were applied. In these first 16 cases, dressings were
then changed every two days and reassessment was
performed by an attending physician. To ensure proper
and repeated wound bed evaluation, we abstained from
using dermal substitutes or collagen matrices after the
application of NXB.
In SOC, necrosectomy was conducted by Weck knife,
Humby knife or Versajet™ (Smith & Nephew GmbH,
Hamburg, Germany). We usually combined skin transplant-
ation with spray application of fibrin sealant (ARTISS™,
Baxter Deutschland GmbH, Unterschleißheim, Germany)
to assure proper adhesion.
Throughout their stay on BICU, pain levels were mon-
itored every hour, objectified by numeric rating scale
(NRS) and patients received pain medication as required.
Brachial plexus catheters were removed when analgesic
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effect decayed to insufficient levels or determined to be
dispensable. Wound healing, signs of infection or other
complications were assessed every two days by the attend-
ing physician when change of dressings took place. Follow-
ing ED, physical therapy was started as soon as dressings
would allow treatment by a professional therapist.
About 3 months after demission, patients were evalu-
ated for remaining functional disabilities and pain levels
using two German self-report questionnaires (Disabilities
of the Shoulder, Arm and Hand – DASH; Patient-Related
Wrist Evaluation Score – PRWE-G) as well as scar quality
by a single physician (Vancouver Scar Scale – VSS).
Fig. 1 Ludwigshafen treatment algorithm for deep partial- to full-thickness burns involving the upper extremities
Fig. 2 ED treatment phases
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Results
Sixteen patients (11 male, 5 female) with burns of
20.1 (2–66) % TBSA were included in the study. On the
upper extremities, 7.3 (2–15) % TBSA were classified as
deep partial- to full-thickness and treated by ED 24.4 (5–47)
hours after injury (Table 1). NXB proved to be very effective
in achieving a complete initial debridement for all cases.
Individual data sets are provided as supplemental file,
see Additional file 1: Raw data.
Three patients deceased due to severity of accompanying
injuries and therefore withdrew from follow-up. Out of the
remaining 13, 7 patients completely avoided surgical inter-
vention as necrosectomy by ED alone led to satisfactory
wound healing. 6 required additional surgical debridement
and skin grafting of 4.6 (0.5–12) % TBSA, equaling a 37.0 %
reduction of transplanted skin area when compared to
initial assessment. After ED patients were able to start PT
after 2.0 (0–5) days but experienced prolonged wound
closure with 28.0 (9–49) days on average.
Seven patients had been intubated on admission due
to the severity of their injuries and were fully sedated
during ED. According to the severity of the injury, patients
underwent either p.o./i.v. pain medication (n = 3) or a
brachial plexus nerve block was applied (n = 6). Regionally
administered anesthesia proved to be superior to pain
medication alone. Pain level, objectified by numeric rating
scale (NRS), was 3.4 (1.1–5.2) in general analgesia
and 2.9 (1.8–4.1) in plexus block group. This was ac-
companied by a 77.2 % reduction of morphine-
equivalent consumed as general anesthesia group re-
quired 9.2 (0.0–17.2) mg/h and regional analgesia group
required 2.1 (0.3–7.0) mg/h (Fig. 5).
Fig. 3 Active NXB agent after mixing powder ingredient and carrier gel
Fig. 4 NXB application phase. a Forming of occlusive dressing by
self-adhesing sheets. Plexus catheter already in place. b Completed
dressing and active enzymatic reaction as indicated by bleeding
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No wound infections or ED-related side effects were
seen. No blood transfusions were necessary.
Eight of 16 patients (50.0 %) were available for follow-
up examination regarding remaining pain levels and
functional outcomes. Results were within the lowest
quarter of the scoring range with 23/100 (0–45) points
on DASH and 22/100 (1–46) points on PRWE-G. Over-
all scar quality was assessed as 6/14 (4–8) points on
VSS. All follow-up examinations were conducted by the
same physician. 3 patients (37.5 %) complained about
increased skin susceptibility of ED treated areas. Reports
consisted of persisting lesioning (Fig. 6), partly spontan-
eous but mostly induced by minimal sheer stress or
otherwise negligible, everyday trauma.
Discussion
ED enabled patients to receive early initial debridement.
With bedside application being practicable, patients
would remain on ward and avoid cost-consuming surgical
and anesthetic measures conducted in the OR. Also, in
SOC, some days are usually allowed for wounds to
completely demarcate the areas requiring necrosectomy and
skin grafting, which further enhances time to debridement.
In our Burn Center, we were able to perform initial
debridement 24.4 h after admission. ED phases itself will
add up to at least 8 h of treatment (Fig. 2) and should
therefore be started preferably in morning hours. Pre-
ceding plexus catheter placement further increases time
by usually 1 or 2 h, rendering ED a long, laborsome pro-
cedure. We found this to be a limitation worth mention-
ing as ED requires a surgeon and nursing staff to be
present at all times during the procedure.
ED reduced the % TBSA treated with surgical necro-
sectomy and skin grafting. Initial assessment of burn
Fig. 5 Comparison of general analgesia and regional anesthesia during ED. a Lower NRS scores in plexus catheter group. b Higher
morphine-equivalent dose in general analgesia
Table 1 Patient injury and treatment characteristics
Characteristic
Epidemiology
Number of patients treated
Mean age (SD), years
Males, no. (%)
Females, no. (%)







Mean (SD) % TBSA
Mean (SD) % TBSA treated by ED
Patients requiring skin grafting after ED, no. (%)
Mean (SD) time to skin grafting after ED, days
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extent and depth is difficult and needs to be perman-
ently scrutinized and reevaluated. Especially in the first
days after injury, wounds can both progress or turn out
to be overestimated by the admitting physician. The latter
will result in unnecessary surgical interventions and mor-
bidity, especially on delicate structures such as fingers and
hands. In more than half of our collective initially classi-
fied as candidates for surgery, ED totally avoided necro-
sectomy and skin grafting. In the remaining patients,
transplanted area was substantially smaller than initially
anticipated, minimizing associated complications such as
donor site morbidity, contractures and aesthetic disadvan-
tages. Patients, however, exhibited prolonged wound
healing and at least 14 days of close observation were
allowed before additional debridement and skin graft-
ing could be ruled out.
No differentiation was made between the treatment of
deep partial- and full-thickness burns as NXB is ap-
proved for both. But experiences show that areas early
identified as full-thickness often lacked any self-healing
activity after ED. Furthermore, full-thickness wounds
that successfully healed after ED were often observed
with intense scar vascularization and discoloration as
well as increased susceptibility to trauma (Fig. 6). Based
on these findings, we changed our policy to earlier skin
grafting of full-thickness areas after ED, actually combin-
ing SOC and ED (Fig. 1).
In these first 16 ED patients, no dermal substitutes or
collagen matrices were used as application would have
interfered with repeated wound assessment. However,
products such as Matriderm™ (Dr. Suwelack Skin &
Health Care AG, Billerbeck, Germany), Integra™ (Integra
GmbH, Ratingen, Germany), Suprathel™(Polymedics In-
novations GmbH, Denkendorf, Germany) and Biobrane™
(Smith & Nephew GmbH, Hamburg, Germany) are
generally available and used in our Burn Center.
Additional methods include allo- or xenografting and
spray-on epidermal cells (Recell™, Avita Medical, Melbourn,
United Kingdom). These products will presumably further
facilitate burn wound consolidation but their exact effect
on NXB treated areas is unknown and something we
tend to elucidate in future investigations.
In our experience, ED does not necessarily require
intubation and sedation, usually conducted in SOC. Pain
is generally well tolerated by on ward anesthetic mea-
sures, with regionally administered analgesia being more
effective when compared to p.o./i.v. medication alone.
Ultrasound-guided placement of brachial plexus nerve
blocks is safe and excludes morbidity possibly associated
with intubation and sedation. These patients also exhibit
decreased opioid doses essentially achieved by a continu-
ously infused local anesthetic (mepivacaine or ropivacaine).
Due to their additional anti-inflammatory properties,
NSAIDs were given in both groups and were there-
fore not evaluated.
Grafted areas are immobilized for at least 5 days to en-
sure proper skin adhesion. This unfortunately excludes
these regions from PT and subsequently leads to con-
tractures, movement restrictions and often prolonged
functional recovery. With ED, patients benefitted from
early onset of PT measures, mostly on the first or
Fig. 6 Three representative patients before and after ED. a and b Closed wounds 23 weeks after treatment. Note the intense vascularization in
originally full-thickness affected areas. c and d Good results 16.5 weeks after ED. e and f Unstable scars with possibly sheer stressed induced
interdigital lesioning still present after 18 weeks
Table 2 Applied NXB exclusion criteria
NXB contraindications as listed by manufacturer (see [7])
Hypersensitivity to the active substance, to pineapples or papain or
to any of the excipients
Additional exclusion criteria applied in our Burn Center
Pregnant and nursing women,
Chemical or electrical burns,
Age of burn injury >48 h
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second day after admission. 3-month follow-up also
yielded good functional outcomes and pain levels.
Conclusions
In conclusion, we see a potential benefit for ED in the
treatment of deeply burned hands and arms but careful
observation must be assured as full-thickness involve-
ment might require treatment adjustments, possibly
neglecting associated benefits. We found regional
anesthesia by brachial plexus catheter being superior to
pain medication alone but availability might be limited
as placement usually requires a skilled anesthesiologist.
Some patients complained of persistent lesioning and
hypertrophic scarring which we attributed to our pro-
longed waiting for reepithelialization. Based on these
findings, the following protocol is currently applied at
our Burn Center (Fig. 1): All admitted patients with deep
partial- to full-thickness burns of the upper extremities
not meeting exclusion criteria (Table 2) will undergo ED
within the first 48 h after trauma (1st Assessment), prefer-
ably accompanied by regional anesthesia via brachial
plexus blockage. Two days later, during dressing changes,
the patient is again evaluated for areas of demarcated
full-thickness involvement (2nd Assessment), which
would then be treated by additional necrosectomy and
skin grafting. Absence of these would rule out SOC and
allow wounds to consolidate for at least 2 more weeks
before surgery is again taken into consideration.
We hereby report our experiences in using ED on 16
patients with deep partial- to full-thickness burns of the
upper extremities. Although group size is small and
obviously lacking appropriate controls, we feel that our
observations will be of interest to any NXB using burn
surgeon. Certain problems and obstacles had us adjust our
initial treatment protocol but this current standard is solely
based on expert opinion and clinical experience. Further
investigations and prospective randomized controlled stud-
ies will be required to statistically support our conclusions.
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